Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates.
作者信息
Masuda Daisaku
机构信息
Rinku General Medical Center, Rinku Innovation Center for Wellness Care and Activities (RICWA), Health Care Center, Department of Cardiology.
出版信息
J Atheroscler Thromb. 2023 May 1;30(5):429-431. doi: 10.5551/jat.ED216. Epub 2022 Oct 9.
Abstract
摘要
相似文献
1
Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates.与贝特类药物相比，使用 Pemafibrate 降低甘油三酯水平及心血管风险
J Atheroscler Thromb. 2023 May 1;30(5):429-431. doi: 10.5551/jat.ED216. Epub 2022 Oct 9.
2
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?过氧化物酶体增殖物激活受体α 调节剂（SPPARMα）：降低慢性肾脏病患者残余心血管风险的新机遇？
Curr Atheroscler Rep. 2020 Jul 15;22(8):43. doi: 10.1007/s11883-020-00860-w.
3
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.非诺贝特，一种新型选择性过氧化物酶体增殖物激活受体 α 调节剂：药物概念及其在血脂异常和代谢性疾病中的临床应用。
Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5.
4
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.依帕司他治疗糖尿病周围神经病变的系统评价和 Meta 分析
Cardiovasc Diabetol. 2021 May 4;20(1):96. doi: 10.1186/s12933-021-01291-w.
5
Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease.非诺贝特和其他降低甘油三酯的治疗方法可降低心血管和代谢疾病风险。
Curr Opin Cardiol. 2024 Jul 1;39(4):286-291. doi: 10.1097/HCO.0000000000001136. Epub 2024 Mar 11.
6
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.选择性PPARα调节剂K-877（匹伐贝特）在接受他汀类药物治疗的欧洲患者中的疗效和安全性。
Diabetes Care. 2022 Apr 1;45(4):898-908. doi: 10.2337/dc21-1288.
7
[The PROMINENT trial: swan song of the fibrates].[显著试验：贝特类药物的绝唱]
Ned Tijdschr Geneeskd. 2023 Apr 5;167:D7528.
8
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.新型选择性过氧化物酶体增殖物激活受体 α 调节剂 pemafibrate 在血脂异常和代谢性疾病中的临床应用。
J Atheroscler Thromb. 2019 May 1;26(5):389-402. doi: 10.5551/jat.48918. Epub 2019 Mar 30.
9
Limited benefit of triglyceride lowering with fibrates in statin-treated patients.在接受他汀类药物治疗的患者中，使用贝特类药物降低甘油三酯的益处有限。
Nat Rev Cardiol. 2023 Jan;20(1):4. doi: 10.1038/s41569-022-00814-6.
10
Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.选择性过氧化物酶体增殖物激活受体 α 调节剂（SPPARMα）：下一代过氧化物酶体增殖物激活受体 α 激动剂。
Cardiovasc Diabetol. 2013 May 31;12:82. doi: 10.1186/1475-2840-12-82.
引用本文的文献
1
Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study.Pemafibrate在血脂异常合并严重肾功能损害患者中的药代动力学和安全性：一项4期研究。
J Atheroscler Thromb. 2025 Feb 1;32(2):210-225. doi: 10.5551/jat.64887. Epub 2024 Sep 5.
2
Deteriorative Effect of a Combination of Hypertriglyceridemia and Low High-Density Lipoprotein Cholesterolemia on Target Lesion Revascularization after Everolimus-Eluting Stent Implantation.高甘油三酯血症和低高密度脂蛋白胆固醇血症联合对依维莫司洗脱支架置入后靶病变血运重建的恶化影响。
J Atheroscler Thromb. 2023 Dec 1;30(12):1778-1790. doi: 10.5551/jat.64010. Epub 2023 Apr 25.
本文引用的文献
1
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.日本动脉粥样硬化协会（JAS）2022年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19.
2
Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.非诺贝特与苯扎贝特治疗高甘油三酯血症患者的疗效和安全性：一项随机交叉研究。
J Atheroscler Thromb. 2023 May 1;30(5):443-454. doi: 10.5551/jat.63659. Epub 2022 Jun 28.
3
Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease.匹伐他汀显著改善了非酒精性脂肪性肝病患者的肝功能检查值和纤维化标志物。
Yonago Acta Med. 2020 Aug 7;63(3):188-197. doi: 10.33160/yam.2020.08.009. eCollection 2020 Aug.
4
Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.非诺贝特，一种选择性过氧化物酶体增殖物激活受体α调节剂，可预防非酒精性脂肪性肝炎的发生而不降低肝内甘油三酯含量。
Sci Rep. 2020 May 8;10(1):7818. doi: 10.1038/s41598-020-64902-8.
5
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.降脂治疗与多种降脂治疗类别降低心血管风险的关联：一项随机对照试验的系统评价和荟萃回归分析。
Circulation. 2019 Oct 15;140(16):1308-1317. doi: 10.1161/CIRCULATIONAHA.119.041998. Epub 2019 Sep 18.
6
Postprandial Hyperlipidemia and Remnant Lipoproteins.餐后高脂血症与残留脂蛋白
J Atheroscler Thromb. 2017 Feb 1;24(2):95-109. doi: 10.5551/jat.RV16003. Epub 2016 Nov 8.
7
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.测定血脂谱通常不需要禁食：临床和实验室意义，包括在理想浓度切点处标记——欧洲动脉粥样硬化学会和欧洲临床化学与检验医学联合会联合共识声明
Eur Heart J. 2016 Jul 1;37(25):1944-58. doi: 10.1093/eurheartj/ehw152. Epub 2016 Apr 26.
8
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.新型选择性过氧化物酶体增殖物激活受体α调节剂（SPPARMα）K-877对血脂异常患者的影响：一项随机、双盲、活性药物与安慰剂对照的2期试验。
Atherosclerosis. 2016 Jun;249:36-43. doi: 10.1016/j.atherosclerosis.2016.02.029. Epub 2016 Feb 26.
9
Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009).日本心血管疾病及其危险因素的长期变化趋势：从 1961 年到 2009 年的平山研究数据。
Circulation. 2013 Sep 10;128(11):1198-205. doi: 10.1161/CIRCULATIONAHA.113.002424. Epub 2013 Jul 31.
10
Effects of combination lipid therapy in type 2 diabetes mellitus.2 型糖尿病的联合降脂治疗效果。
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.
Zotero 插件